- Home
- KPLT vs GRCE Comparison
KPLT vs GRCE Comparison
Compare KPLT & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- GRCE
- Stock Information
- Founded
- KPLT 2012
- GRCE 2002
- Country
- KPLT United States
- GRCE United States
- Employees
- KPLT N/A
- GRCE N/A
- Industry
- KPLT Diversified Commercial Services
- GRCE
- Sector
- KPLT Consumer Discretionary
- GRCE
- Exchange
- KPLT Nasdaq
- GRCE NYSE
- Market Cap
- KPLT 35.6M
- GRCE 41.2M
- IPO Year
- KPLT N/A
- GRCE N/A
- Fundamental
- Price
- KPLT $6.71
- GRCE $2.70
- Analyst Decision
- KPLT Hold
- GRCE Strong Buy
- Analyst Count
- KPLT 2
- GRCE 1
- Target Price
- KPLT $12.00
- GRCE $12.00
- AVG Volume (30 Days)
- KPLT 34.5K
- GRCE 26.6K
- Earning Date
- KPLT 05-15-2025
- GRCE 05-27-2025
- Dividend Yield
- KPLT N/A
- GRCE N/A
- EPS Growth
- KPLT N/A
- GRCE N/A
- EPS
- KPLT N/A
- GRCE N/A
- Revenue
- KPLT $247,194,000.00
- GRCE N/A
- Revenue This Year
- KPLT $20.12
- GRCE N/A
- Revenue Next Year
- KPLT $13.19
- GRCE N/A
- P/E Ratio
- KPLT N/A
- GRCE N/A
- Revenue Growth
- KPLT 11.56
- GRCE N/A
- 52 Week Low
- KPLT $5.08
- GRCE $1.75
- 52 Week High
- KPLT $23.54
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- KPLT 33.40
- GRCE N/A
- Support Level
- KPLT $6.80
- GRCE N/A
- Resistance Level
- KPLT $7.75
- GRCE N/A
- Average True Range (ATR)
- KPLT 0.50
- GRCE 0.00
- MACD
- KPLT 0.09
- GRCE 0.00
- Stochastic Oscillator
- KPLT 31.13
- GRCE 0.00
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.